Follicular Lymphoma — Where We Are, Where We're Headed in the Use of Bispecific Antibodies
From Hematologic Oncology Update · 57:54
Show by Dr. Neil Love
Featuring perspectives from Prof Chan Chea and Dr Matthew Matasar, including the following topics:Introduction (0:00)Prologue: Saturday Night Fever (1:35)Baby Boomers' Guide to Mechanisms of Action (3:07)Second-Line Treatment (12:36)Complications Associated with Bispecific Antibodies (23:41)Case Presentations (25:52)New Bispecific T-Cell Engagers — Surovatamig (26:24)Other Novel Agents (50:05)CME information and select publications
More episodes of Hematologic Oncology Update
More episodes
- GPRC5D-Directed Therapies for Multiple Myeloma — An Interview with Prof Rakesh Popat
- Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 3: An Interview with Dr Matthew Lunning on The Utility of Tafasitamab
- Relapsed/Refractory Multiple Myeloma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
- Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens
- Diffuse Large B-Cell Lymphoma — A Grand Rounds Program
- Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 1: An Interview with Dr Matthew Lunning on CNS Prophylaxis
- Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 6
- Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 5
- Non-Hodgkin Lymphoma — A Roundtable Discussion on CD20 x CD3 Bispecific Antibodies and the Optimal Management of Cytokine Release Syndrome
- Chronic Lymphocytic Leukemia — Microlearning Activity 2
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.